The Life Sciences team advised Generate:Biomedicines on the closing of its $273 million Series C. The financing round attracted many new investors including Amgen; NVentures, NVIDIA’s venture capital arm; MAPS Capital (Mirae Asset Group); and Pictet Alternative Advisors. Additionally, company founder, Flagship Pioneering, and every Series B investor, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA); Fidelity Management & Research Company; funds and accounts advised by T. Rowe Price Associates, Inc.; ARCH Venture Partners; and March Capital, participated in the round.
Generate:Biomedicines has raised nearly $700 million in equity financing since 2020. The company has a robust pipeline of 17 programs in preclinical and clinical development across oncology, immunology, and infectious disease. Generate:Biomedicines will leverage Series C funding to further its pipeline, including filing multiple INDs in 2024 and initiating multiple clinical trials annually thereafter.
For additional details on the funding round, please read the press release.